Sarepta Therapeutics (NASDAQ:SRPT) Given New $84.00 Price Target at JPMorgan Chase & Co.
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target cut by research analysts at JPMorgan Chase & Co. from $169.00 to $84.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target would suggest a […]
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target cut by research analysts at JPMorgan Chase & Co. from $169.00 to $84.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target would suggest a […]
